卵巢癌
生物标志物
尿
医学
生物标志物发现
肿瘤科
间皮素
内科学
癌症
疾病
蛋白质组学
生物
生物化学
基因
作者
Jarrod J. Sandow,Adam Rainczuk,Giuseppe Infusini,Ming Makanji,Maree Bilandzic,Amy L. Wilson,Nicole Fairweather,Peter G. Stanton,Daniel J. Garama,Daniel Gough,Thomas W. Jobling,Andrew I. Webb,Andrew N. Stephens
标识
DOI:10.1002/prca.201700135
摘要
For the vast majority of ovarian cancer patients, optimal surgical debulking remains a key prognostic factor associated with improved survival. A standardized, biomarker-based test, to preoperatively discriminate benign from malignant disease and inform appropriate patient triage, is highly desirable. However, no fit-for-purpose biomarkers have yet been identified.We conducted a pilot study consisting of 40 patient urine samples (20 from each group), using label-free quantitative (LFQ) mass spectrometry, to identify potential biomarker candidates in urine from individual ovarian cancer patients. To validate these changes, we used parallel reaction monitoring (PRM) to investigate their abundance in an independent validation cohort (n = 20) of patient urine samples.LFQ analyses identified 4394 proteins (17 027 peptides) in a discovery set of 20 urine samples. Twenty-three proteins were significantly elevated in the malignant patient group compared to patients with benign disease. Several proteins, including LYPD1, LYVE1, PTMA, and SCGB1A1 were confirmed to be enriched in the urine of ovarian cancer patients using PRM. We also identified the established ovarian cancer biomarkers WFDC2 (HE4) and mesothelin (MSLN), validating our approach.This is the first application of a LFQ-PRM workflow to identify and validate ovarian cancer-specific biomarkers in patient urine samples.
科研通智能强力驱动
Strongly Powered by AbleSci AI